Vigil Neuro
Pamela Meneses is an experienced finance professional currently serving as the VP and Controller at Vigil Neuroscience since April 2021. Prior to this role, Pamela held the position of Sr. Director of External Reporting and Technical Accounting at Akebia Therapeutics from December 2017 to April 2021, following several years at EY where Pamela advanced from Audit Senior to Audit Senior Manager between September 2006 and December 2017. Pamela holds an MBA/MSA from Northeastern University and a BS from Tulane University’s A.B. Freeman School of Business.
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.